Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ligand Pharmaceuticals Q2 Adj. EPS $1.60 Beats $1.42 Estimate, Sales $47.627M Beat $43.870M Estimate

Author: Benzinga Newsdesk | August 07, 2025 07:02am
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.42 by 12.6 percent. This is a 14.29 percent increase over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $47.627 million which beat the analyst consensus estimate of $43.870 million by 8.56 percent. This is a 14.68 percent increase over sales of $41.531 million the same period last year.

Posted In: LGND


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist